Leerink Partners Boosts Twist Bioscience (NASDAQ:TWST) Price Target to $48.00

Twist Bioscience (NASDAQ:TWST) had its price target raised by analysts at Leerink Partners from $45.00 to $48.00 in a note issued to investors on Thursday, Benzinga reports. The firm presently has a “market perform” rating on the stock. Leerink Partners’ target price suggests a potential upside of 4.58% from the stock’s current price.

Several other brokerages also recently commented on TWST. Barclays decreased their target price on shares of Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating on the stock in a research note on Monday, August 5th. Robert W. Baird lifted their target price on shares of Twist Bioscience from $40.00 to $46.00 and gave the company an “outperform” rating in a research note on Monday, August 5th. The Goldman Sachs Group increased their price target on shares of Twist Bioscience from $45.00 to $55.00 and gave the stock a “buy” rating in a research note on Tuesday, July 9th. Evercore ISI lifted their price objective on Twist Bioscience from $52.00 to $56.00 and gave the company an “outperform” rating in a research report on Tuesday, October 1st. Finally, JPMorgan Chase & Co. upped their target price on Twist Bioscience from $28.00 to $35.00 and gave the stock an “underweight” rating in a report on Monday, August 5th. One research analyst has rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, Twist Bioscience presently has an average rating of “Moderate Buy” and a consensus price target of $51.22.

Twist Bioscience Stock Up 1.8 %

Shares of Twist Bioscience stock traded up $0.83 during trading on Thursday, reaching $45.90. The company’s stock had a trading volume of 188,665 shares, compared to its average volume of 965,145. The company has a market cap of $2.69 billion, a price-to-earnings ratio of -12.02 and a beta of 1.77. The firm’s 50-day moving average is $43.91 and its two-hundred day moving average is $44.20. Twist Bioscience has a 52-week low of $14.42 and a 52-week high of $60.90.

Twist Bioscience (NASDAQ:TWST) last released its quarterly earnings data on Friday, August 2nd. The company reported ($1.47) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.71). The company had revenue of $81.50 million during the quarter, compared to analysts’ expectations of $77.40 million. Twist Bioscience had a negative return on equity of 32.17% and a negative net margin of 74.63%. The firm’s quarterly revenue was up 27.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($1.01) EPS. On average, equities research analysts anticipate that Twist Bioscience will post -3.13 EPS for the current year.

Insider Buying and Selling

In other Twist Bioscience news, COO Patrick John Finn sold 2,207 shares of the firm’s stock in a transaction dated Tuesday, July 23rd. The shares were sold at an average price of $56.62, for a total transaction of $124,960.34. Following the completion of the sale, the chief operating officer now directly owns 171,212 shares in the company, valued at approximately $9,694,023.44. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Twist Bioscience news, CFO Adam Laponis sold 856 shares of Twist Bioscience stock in a transaction that occurred on Wednesday, October 9th. The shares were sold at an average price of $41.81, for a total value of $35,789.36. Following the completion of the sale, the chief financial officer now owns 73,397 shares of the company’s stock, valued at approximately $3,068,728.57. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, COO Patrick John Finn sold 2,207 shares of the firm’s stock in a transaction on Tuesday, July 23rd. The stock was sold at an average price of $56.62, for a total value of $124,960.34. Following the completion of the transaction, the chief operating officer now owns 171,212 shares in the company, valued at approximately $9,694,023.44. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 42,246 shares of company stock worth $1,829,356 in the last quarter. Corporate insiders own 3.92% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. EdgeRock Capital LLC purchased a new position in shares of Twist Bioscience in the second quarter worth approximately $43,000. Blue Trust Inc. grew its position in shares of Twist Bioscience by 2,912.8% during the 2nd quarter. Blue Trust Inc. now owns 1,175 shares of the company’s stock valued at $58,000 after acquiring an additional 1,136 shares during the period. DekaBank Deutsche Girozentrale purchased a new stake in shares of Twist Bioscience in the 2nd quarter worth $61,000. Nisa Investment Advisors LLC raised its holdings in Twist Bioscience by 31.3% in the 2nd quarter. Nisa Investment Advisors LLC now owns 2,288 shares of the company’s stock worth $113,000 after purchasing an additional 546 shares during the period. Finally, CWM LLC lifted its position in Twist Bioscience by 27.4% during the second quarter. CWM LLC now owns 2,437 shares of the company’s stock valued at $120,000 after purchasing an additional 524 shares in the last quarter.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.